WHO Director-General Tedros Adhanom Ghebreyesus on May 17 warned that “The pandemic is a long way far from over. It will not be over anywhere until it’s over anywhere.” A severe vaccine shortage, as well as questions about its effectiveness, in addition to the virus’s constant mutation, reinforce Tedros’ assertion.

Ghebreyesus said: “Even some places that have previously done very well at containing COVID-19 are seeing dramatic increases in cases, hospitalizations and deaths.”

“In some countries with the highest vaccination rates, there appears to be a mindset that the pandemic is over—while others are experiencing huge waves of infection,” said the WHO Director-General, and mentioned the pandemic situation is very serious in India.

Ghebreyesus also said that the sharp increase in Chinese Communist Party (CCP) Virus (COVID-19) cases had caused an increasing shortage of vaccines. WHO’s COVAX (COVID-19 Vaccine Access Initiative) program will be short of 190 million doses by the end of June.

More importantly, WHO is running out of money to fund its vaccine program. Ghebreyesus stated that the WHO requires quick funding because of the “high demand” for the program.

Natural News quoted pharmaceutical companies saying they were $19 billion short of completing the vaccine production plan this year. Meanwhile, Ghebreyesus noted that an additional $35-45 billion is needed to ensure that most of the world’s adults are immunized against the virus that originated in China.

Another factor that may prevent a CCP Virus (COVID-19) vaccine from being quickly approved by the public, even if it is available, is the safety and effectiveness of the vaccine.

All the vaccines being distributed in the United States right now are authorized for emergency use only, including those of Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson), meaning that none of them are “approved.”

The FDA only granted Pfizer the Emergency Use Authorization (EUA) last year as the United States was indisputably in an urgent state as the CCP virus was prevailing. The vaccine got a pass after only two months of trials. In comparison, the Biologics License Application (BLA) demands at least six months of study on no less than 3,000 participants to clarify the drug’s potential side effects.

Dr. Peter Doshi, the editor of the British Medical Journal, was doubtful about the length of the trials for the FDA to approve BLA. He said that the trials of the CCP Virus vaccines were authorized “the fastest” in the medical agency’s history. He explains that since 2006 vaccines for other diseases were usually screened through after 23 months of trials, nearly four times as long as those used to trial the CCP Virus.

“On paper, the phase III studies by Pfizer, Moderna, and Janssen are all of two years’ duration,” the outlet noted.

An FDA document reveals that 86% of children between the ages of 12 and 15 who participated in Pfizer vaccine trials experienced adverse effects.

Additionally, there are many reports of deaths resulting from vaccination, and other cases show people are still infected with the virus despite having been fully vaccinated.

Some scientists say the CCP Virus continuously mutates into dangerous variants that can avoid or resist the vaccine. If that is the case, the CCP Virus pandemic end date is indeterminate.

Sign up to receive our latest news!

By submitting this form, I agree to the terms.